Abstract

Objectives—NACP/α-synuclein is an aetiological gene product in familial Parkinson’s disease. To clarify the pathological role of NACP/α-synuclein in sporadic Parkinson’s disease and other related disorders including diffuse Lewy body disease (DLBD) and multiple system atrophy (MSA), paraffin sections were examined immunocytochemically using anti-NACP/α-synuclein antibodies.

Methods—A total of 58 necropsied brains, from seven patients with Parkinson’s disease, five with DLBD, six with MSA, 12 with Alzheimer’s disease, one with Down’s syndrome, one with amyotrophic lateral sclerosis (ALS), three with ALS and dementia, one with Huntington’s disease, two with progressive supranuclear palsy (PSP), one with Pick’s disease, one with myotonic dystrophy, and three with late cerebellar cortical atrophy (LCCA), and 15 elderly normal controls were examined.

Results—In addition to immunoreactive Lewy bodies, widespread accumulation of NACP/α-synuclein was found in neurons and astrocytes from the brainstem and basal ganglia to the cerebral cortices in Parkinson’s disease/DLBD. NACP/α-synuclein accumulates in oligodendrocytes from the spinal cord, the brain stem to the cerebellar white matter, and inferior olivary neurons in MSA. These widespread accumulations were not seen in other types of dementia or spinocerebellar ataxia.

Conclusion—Completely different types of NACP/α-synuclein accumulation in Parkinson’s disease/DLBD and MSA suggest that accumulation is a major step in the pathological cascade of both diseases and provides novel strategies for the development of therapies.

Keywords: Parkinson’s disease; multiple system atrophy; NACP; α-synuclein

Parkinson’s disease, first described by James Parkinson in 1817, is the third most common neurological disease after cerebrovascular disease and Alzheimer’s disease. A loss of pigmented neurons, gliosis, and eosinophilic cytoplasmic inclusions called Lewy bodies in the remaining neurons in the substantia nigra are the most constant pathological findings in Parkinson’s disease. Although treatment with levodopa or dopamine receptor agonists based on the depletion of striatal dopamine markedly improves parkinsonism, patients with Parkinson’s disease still become disabled within 5 to 10 years with the advancement of disease. A non-Aβ component of Alzheimer’s disease amyloid (NAC) was identified as the second intrinsic component in amyloid from Alzheimer’s disease brains. The cloned NAC precursor protein termed NACPα (also called α-synuclein), a presynaptic nerve terminal protein, has been identified as the causal gene product in five families with Parkinson’s disease (one Italian and three Greek families and one German family). To clarify the pathological role of NACP in sporadic Parkinson’s disease and other related disorders including diffuse Lewy body disease (DLBD) and multiple system atrophy (MSA), paraffin sections were examined immunocytochemically in the present study.

Materials and methods

A total of 58 necropsied brains from seven patients with Parkinson’s disease (age 64–81), five with DLBD (age 73–84), six with ALS (age 51–66), 12 with Alzheimer’s disease (age 48–95), one with Down’s syndrome, one with amyotrophic lateral sclerosis (ALS), three with ALS and dementia, one with Huntington’s disease, two with progressive supranuclear palsy (PSP), one with Pick’s disease, one with myotonic dystrophy, three with late cerebellar cortical atrophy (LCCA), and 15 elderly normal controls (age 45–91) were examined. The diagnosis of DLBD was based on the clinical criteria of the DLB international workshop for dementia with Lewy bodies and the pathological appearance of many cortical Lewy bodies detected using haematoxylin and eosin staining.

The anti-NACP antibodies: MDV13—a polyclonal antibody against a synthetic 15 amino acid peptide of the N-terminus of NACP; NACPN—a polyclonal antibody against a synthetic 30 amino acid peptide of the N-terminus of NACP; NACPS—a polyclonal antibody against a synthetic 30 amino acid peptide of the C-terminus of NACP; and anti-NAC domain antibody (EQV)13—a polyclonal antibody against 15 amino acid peptides of the N-terminus of NAC were used at a dilution of 1:1000. Paraffin sections were pretreated with 99% formic acid for 3 minutes, incubated...
with primary antibodies for 3 hours, and then immunostained using an ABC immunostaining kit (Vector, Burlingame, CA, USA). Haematoxylin was used for nuclear staining. These preimmune sera did not show any immunoreactivity in any sections.

Results
In the Parkinson’s disease brains, all antibodies—MDV, NACPN, EQV, and NACPC—labelled many Lewy bodies in the substantia nigra and locus ceruleus, as reported previously.14–16 (fig 1 C arrow head). In addition, many small granules in neurons (fig 1 C and D), a giant swelling of neuronal processes, and many dystrophic neurites (fig 1 E) were detected in the grey matter from the pons and midbrain to the basal ganglia and cerebral cortex. Extensive dystrophic neurites and intraneuronal granules in basal ganglia (fig 1 B), a moderate number of dystrophic neurites, and a few cortical-type Lewy bodies in the cerebral cortices (fig 1 A) were recognised. Another interesting finding was the presence of immunoreactive astrocytes in Parkinson’s disease brains (fig 1 A). The severity of the immunoreactive astrocytosis was correlated with the appearance of cortical Lewy bodies and dystrophic neurites. These immunoreactivities were not detected in cerebral white matter, cerebellar white or grey matter, crus cerebri (fig 1 F), or the white and grey matter of the lower brainstem and spinal cord. All antibodies—MDV, NACPN, EQV, and NACPC—showed similar immunoreactivities (fig 2).

Disease is the third major cause of dementia after Alzheimer’s disease and vascular dementia.91 0 All antibodies—MDV, NACPN, EQV, and NACPC—labelled many immunoreactive cortical Lewy bodies in the fifth and sixth layers, and dystrophic neurites and prominent astrocytosis in all layers of the cerebral cortex in all cases of DLBD (fig 3 A and B). Although many Lewy bodies, dystrophic neurites, and astrocytes were also recognised in the basal ganglia (fig 3 C), NACP accumulation in the DLBD brainstem was at a similar level as that in the Parkinson’s disease brains (fig 3 E). However, it was not found in the cerebellum (fig 3 D) or lower brainstem.

Marked accumulation of NACP was not seen in the brains of patients with the other kinds of dementia examined here; two cases of progressive supranuclear palsy, one case of Huntington’s disease, one case of Pick’s disease, three cases of amyotrophic lateral sclerosis (ALS) with dementia, and one case of myotonic dystrophy. One ALS brain and all of the 15 elderly normal control brains did not show NACP accumulation. We subsequently examined 12 brains from sporadic Alzheimer’s disease and a Down’s syndrome brain. Although the frozen sections of these brains showed weak immunoreactive senile plaques using the EQV antibody alone, no paraconfigurations from the 12 Alzheimer’s disease brains or the Down’s syndrome brain showed any significant NACP immunoreactivity in neurons, astrocytes, or senile plaques.

Multiple systems atrophy shows varying degrees of parkinsonism, automatic dysfunction, and cerebellar ataxia.11 Recent studies have shown the presence of NACP in glial cytoplasmic inclusions (GCI) in the brainstem and cerebellar white matter.12–20 All MDV, NACPN, EQV, and NACPC antibodies showed extensive distributions of NACP-immunoreactive oligodendrocytes in the cerebellar white matter (fig 4 B), basal ganglia (fig 4 C), brainstem, and spinal cord of the MSA brains. Large accumulations of NACP in

Figure 1  Immunostaining of NACP/α-synuclein in a parkinsonian brain using MDV antibody (1:1000). A few cortical Lewy bodies, dystrophic neurites, and astrocytes are found in the cerebral cortex (A×160), and basal ganglia (B×160). In the substantia nigra, typical Lewy bodies (C arrow head×320), granular intraneuronal NACP accumulation (C×320), perineurial NACP accumulation (D×320), and giant swelling of neuronal processes are detected (E×160). No immunoreactivity is seen in the crus cerebri in the midbrain (F×160).

Figure 2  Immunostaining of Lewy body in the midbrain of a patient with Parkinson’s disease using MDV, NACPN, EQV, NACPC antibodies. (A) MDV×480; (B) NACPN×480; (C) EQV×480; (D) NACPC×480.
oligodendrocytes were seen in the internal capsule, lateral and medial medullary laminae, putamen, and globus pallidus, crus cerebri (fig 4 D), cerebellar white matter, cerebellar peduncles, pontine basis (fig 4 E), medulla oblongata (fig 4 H), and from the cervical to lumbar spinal cord. These oligodendrocytes were rare in the cerebral grey and white matter (fig 4 A), cerebellar cortex and dentate nuclei, the dorsal part of the brainstem, and the posterior funiculus of the spinal cord. There were accumulations of NACP in neurons and processes in the inferior olivary nucleus alone (fig 4 G). Degenerated cerebellar Purkinje cells and the midbrain pigmented neurons (fig 4 H) were not labelled by any of the antibodies. Such accumulations were not seen in LCCA brains.

Discussion
The findings from Parkinson’s disease brains indicate that molecules of NACP accumulate as small granules in neurons, and as diffuse deposits in neuronal processes, in addition to Lewy bodies. These intracellular accumulations of NACP were distributed more extensively in larger areas than those detected using haematoxylin and eosin staining, which showed only the presence of Lewy bodies and neuronal cell loss in the substantia nigra and other brainstem nuclei, and in intact basal ganglia and cortical cortices in Parkinson’s disease brains. Although NACP is considered to be a synaptic protein, NACP was detected in cortical astrocytes. It accumulates not as a mere component of Lewy bodies, but as independent deposits with abnormal structures in neural/astrocytic cell systems more extensively than those detected using conventional pathological examination. These newly detected widespread accumulations of NACP may disturb connections between the brainstem and basal ganglia, and among nuclei in the basal ganglia, and may be another origin of clinical parkinsonism, as seen in secondary Parkinson’s syndrome.

The distribution and the cell type of NACP accumulation were essentially the same in the Parkinson’s disease and DLBD brains. The only difference was the appearance of more Lewy bodies, dystrophic neurites, and astrocytes in the basal ganglia and the cortex of DLBD brains. These findings suggest that DLBD is essentially identical to Parkinson’s disease in terms of NACP accumulation. The diffuse damage to cerebral cortices by severe astrocytosis, Lewy bodies, and dystrophic neurites may cause clinical dementia in DLBD.

The parafoveal embedding may have caused the loss of the epitope of the NAC domain in senile plaques, as previously demonstrated. These findings suggested that the newly detected intracellular accumulations of NACP are a specific event in Lewy body disease (Parkinson’s disease and DLBD) by contrast with Alzheimer’s disease, where extracellular accumulations of degradation fragments of NACP, such as NAC, occur with Aβ amyloid deposits. As reactive astrocytes in the brains with other diseases were not labelled by NACP antibodies, the appearance of immunoreactive NACP astrocytosis is considered to be specific to Lewy body disease.

NACP accumulates widely and specifically in oligodendroglia and olivary neurons in MSA. These completely different types of accumulation of NACP can easily identify MSA as distinct from Lewy body disease and other neurodegenerative diseases. The conduction disturbances in the subcortical white matter of the basal ganglia, cerebellum, and brainstem due to oligodendrogial damage may be correlated with the complex symptoms of MSA.

As the degraded fragment of NACP, NAC, is a component of extracellular Alzheimer’s amyloid, NACP is a key step in the pathological cascades of major neurodegenerative diseases. The binding of NACP to Aβ is considered to be
Figure 4 Immunostaining of NACP/α-synuclein in a brain with multiple system atrophy (MSA) by MD antibody (1:1000). (A×64) Although no immunoreactivity is seen in the grey and white matter of the cerebral cortex, (B×64) many oligodendrocytes are extensively labelled in the cerebellar white matter. (C×160) These immunoreactive oligodendrocytes are seen in the basal ganglia, (D×320) crus cerebri, and (E×160) putamen basis. (F×320) The midbrain pigmented neurons are not stained. (G×320) NACP/α-synuclein accumulated only in neurons and neurites of the inferior olivary nucleus. (H×64) Many immunoreactive oligodendrocytes are seen in the pyramid in the medulla oblongata.

the pathological origin of amyloid formation. The accumulations of NACP detected in the present study were not stained by Congo red, suggesting that they may not have a significant level of the β-peptide sheet configuration, as seen in senile plaque amyloid (data not shown). Mutant NACP genes of familiar Parkinson's disease are the origins of the pathological cascades. Other upstream factors in the cascades, such as disturbance of axonal transport, proteolytic degradations, and the alternative synthesis of NACP in different cell lines, remain to be clarified. The present findings support the concept that NACP accumulation shares pathological similarities with other neurodegenerative diseases, many of which have recently been shown to involve accumulations of aetiological gene products in the brains.

The study of tau has contributed to clarification of the pathogenesis of many neurodegenerative diseases. Studies on NACP accumulation may provide an understanding of Lewy body disease and MSA and clarify novel strategies for the development of therapies leading to a cure for Lewy body disease and MSA.

This work was supported by the Life Science Foundation, the Sasakawa Health Science Foundation, Uehara Memorial Foundation, the Primary Amyloidosis Research Committee of the Ministry and Welfare of Japan, and the Ministry of Education, Science, and Culture of Japan.

18 Papp M, Lantos PL. Accumulation of tubular structures in oligodendrogial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 1992;107:172–82.